TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · no major macro event
GHRS

GH Research PLC

Healthcare · Biotechnology

22.20$ -3.4% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

GH Research PLC (GHRS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 372 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet GHRS
Line item Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
– – – 5.9 5.6 293 286 280 274 266 260 254 249 240 233 226 218 207 200 188 320 313 302 288 275 372
0.5 – – 5.9 5.5 293 286 280 273 266 260 169 165 166 164 164 160 153 155 154 295 294 295 286 272 369
0.5 – – 5.9 4.6 293 281 277 271 265 257 166 105 97 86 78 77 87 90 101 245 254 250 246 243 345
0.5 – – 5.9 4.6 293 281 277 271 265 257 166 163 165 161 162 158 151 150 149 291 292 289 281 267 363
– – – 0.0 – – 0.0 0.0 – – 0.1 0.1 – – – 0.2 – – – 1.7 – – – 1.3 1.3 –
– – – 0.0 – – 3.0 3.0 – – -0.1 -0.1 – – – -0.2 – – – – – – – – – –
– – – – 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 – 1.2 – – – – – – – – – – – –
-0.4 – – 0.2 1.2 4.6 2.0 2.7 4.1 3.1 3.4 4.5 7.4 7.3 6.8 7.3 7.8 8.3 10 9.3 10 10 11 8.5 12 13
– – – 0.2 1.2 4.6 2.0 2.7 4.1 3.1 3.4 4.5 6.6 6.6 6.1 6.7 7.3 7.8 9.8 9.0 9.9 10.0 10 8.4 12 13
– – – – – – – – – – – – 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.4 0.4
– – – 0.0 0.1 1.0 1.2 0.9 1.5 1.7 1.8 1.9 2.9 2.9 2.7 3.5 3.6 2.6 2.9 3.7 4.8 3.4 3.8 3.8 5.2 5.9
0.4 – – 5.7 4.3 288 284 277 269 263 257 250 242 233 226 219 210 199 189 179 310 303 291 280 263 359
– – – -0.8 -2.0 -4.1 -5.9 -10 -16 -15 -16 -32 -43 -51 -57 -68 -76 -86 -98 -106 -117 -126 -140 -154 -173 -188
28 30 30 30 49 40 52 52 52 52 52 52 52 52 52 52 52 52 52 52 58 62 62 62 62 67

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?